Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Oth­er Blood Prod­ucts

Components of the blood that cannot be assigned to one of the other above-mentioned groups of medicines.

Name Mar­ket­ing Au­tho­ri­sa­tion Hold­er Li­cense Num­ber Li­cense Date Further Information

FEI­BA 500 E.

Take­da GmbH

PEI.H.12158.01.1 20.03.2023

FEI­BA 1000 E.

Take­da GmbH

PEI.H.12158.02.1 20.03.2023

FEI­BA 2500 E.

Take­da GmbH

PEI.H.12158.03.1 20.03.2023

Nor­mosang

Recor­dati Rare Dis­eases

PEI.H.03381.01.1 15.10.2006

On­dexxya

As­trazeneca AB

EU/1/18/1345 26.04.2019

EPAR: On­dexxya

Pro­lastin

Gri­fols Deutsch­land GmbH

12944.01.00 14.12.1988

Pro­lastin 4000 mg

Gri­fols Deutsch­land GmbH

12944.02.00 04.10.2023

Pro­lastin 5000 mg

Gri­fols Deutsch­land GmbH

12944.03.00 04.10.2023

Re­spreeza

CSL Behring GmbH

EU/1/15/1006 20.08.2015

EPAR: Re­spreeza

Disclaimer

The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.

The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.

As of: PEI announcement No. 514 in BAnz AT 01.03.2024 B8.

Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)

Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.

If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.

Updated: 04.03.2024